ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2752

Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome

Emire Seyahi1, Erkan Caglar2, Serdal Ugurlu1, Fatih Kantarci3, Vedat Hamuryudan1, Abdullah Sonsuz4, Melike Melikoglu5, Sebahattin Yurdakul1 and Hasan Yazici5, 1Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2Division of Gastroenterology, Department of Internal Medicine, Bakirkoy Research and Training Hospital, Istanbul, Turkey, 3Department of Radiology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, 4Department of Gastroenterology, Cerrahpasa Medical Faculty of Istanbul Universit, Cerrahpasa Medical Faculty of Istanbul University, Istanbul, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, Hepatic disorders, thrombosis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Behçet’s syndrome (BS) is a well recognized cause of Budd–Chiari syndrome (BCS), however, information about its clinical characteristics and outcome is limited. We had presented the outcome of 40 patients with BCS due to BS at the ACR 2013 meeting (1). In further analyses, we better understood that there were patients in whom BCS could exist without the presence of any liver related symptoms/signs. In the current study we compared demographic, clinical, radiologic and prognostic characteristics of these patients to those presented with overt liver related symptoms.

Methods

We reviewed the records of about 9000 patients with BS who were registered at the multidisciplinary Behçet’s syndrome outpatient clinic at Cerrahpasa Medical Faculty between July 1977 and October 2013. We identified 43 (40 male/ 3 female) patients who were diagnosed as having BCS. Their outcome was evaluated between September 2012 and October 2013.

Results

43 (40 male/ 3 female) patients with BCS were identified. Thirty-three patients (77 %) had presented with liver related symptoms such as ascites and abdominal swelling for a median duration of 1 month [IQR:0.5-2.5 months]. These patients were defined as Group I. On the other hand, 10 (21%) were silent for liver disease at presentation and were found to have BCS while being investigated for fever (n=4), bilateral diffuse leg swelling (n = 4), and pulmonary symptoms like hemoptysis or dyspnea (n =4).  None had liver dysfunction related symptoms/signs. These patients were classified as Group II. All were diagnosed after 1990.  Group II patients were somewhat older (mean age: 32.2 vs 28.7, p=0.26) and had longer disease duration of BS at the onset of BCS (median: 5.1 vs 2.7, p =0.18) than Group I patients. The level of hepatic venous outflow obstruction in Group II involved less frequently the combined IVC and hepatic veins (30 %) while was more likely to involve isolated hepatic veins (30 %) or isolated IVC (40 %) when compared to Group I (76 %, 26 % and 3 %, respectively) (p =0.05).  Besides that, the anatomical distribution of vessels other than those involved in BCS, and the clinical characteristics of BS were not very different than Group I. By the end of the survey, there was only 1 death in Group II, which was not due to hepatic failure.  Mortality was significantly lower among Group I patients (1/10) as compared to Group II (19/33, 58 %), (p =0.025).By the end of the survey, only 1 (1/13) in Group I, had ascites, while in the remaining surviving patients in Group I ascites had resolved within 6 to 8 months after the first visit. A final hepatic Doppler USG indicated that, the frequency of recanalisation and collateral formation was similar between the patients in Group I and II.

Conclusion

There is subgoup of patients in whom, BCS may exist without the presence of liver related symptoms/signs and these patients have a good prognosis . These patients could pass unnoticed, unless one looks carefully for hepatic veins or intra or suprahepatic segments of the IVC. The fact that, 8 of these10 patients were diagnosed after 2000, suggests that this subgroup was recognized after the recent availability of imaging techniques.

References:

Seyahi E et al. ACR 2013


Disclosure:

E. Seyahi,
None;

E. Caglar,
None;

S. Ugurlu,
None;

F. Kantarci,
None;

V. Hamuryudan,
None;

A. Sonsuz,
None;

M. Melikoglu,
None;

S. Yurdakul,
None;

H. Yazici,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/budd-chiari-syndrome-due-to-behcets-syndrome-some-patients-present-without-liver-related-symptoms-and-have-a-better-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology